Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press7110.17650/1994-4098-2012-0-1-13-16MAMMOLOGY. TOPICAL ISSUEМАММОЛОГИЯ. АКТУАЛЬНАЯ ТЕМАBRCA1, BRCA2 mutations — future of predictive oncology: a review of literatureМутации генов BRCA1, BRCA2 — будущее предиктивной онкологии: обзор литературыDmitrievV. N.ДмитриевВ. Н.
Russian Federation
vadd@mail.ruSukhoterinI. V.СухотеринИ. В.
Russian Federation
ZybenkoI. I.ЗыбенкоИ. И.
Russian Federation
DmitrievaT. V.ДмитриеваТ. В.
Russian Federation
Belgorod State National Research UniversityФГАОУ ВПО Белгородский государственный национальный исследовательский университет230220121131623072014230720142012https://ojrs.abvpress.ru/ojrs/article/view/71

In recent years, it has been demonstrated that breast cancer arising in BRCA1 and BRCA2 mutation carriers differs in its morphological, immuno- phenotypic and molecular characteristics from sporadic breast cancer. In addition to improving our understanding of the biology of hereditary breast cancer, the recognition of these differences could also be used to predict BRCA mutation status in a given group of patients.

В исследованиях последних лет продемонстрировано, что рак молочной железы у носителей мутаций генов BRCA1, BRCA2 по сравне- нию со спорадическими случаями имеет морфологические, иммунофенотипические и молекулярные особенности. Изучение данных особенностей позволит не только улучшить наше понимание наследственных форм рака, но также может использоваться для вы- деления групп, подлежащих обследованию на носительство данных мутаций.

BRCA1BRCA2 mutationshereditary breast cancerovarian cancerмутации BRCA1BRCA2наследственный рак молочной железырак яичников1. Textbook of gynaecological oncology. A. Ayhan, M. Gultekin, P. Dursun еds. Ankara, 2012. Сh. 29; p. 191–4.Textbook of gynaecological oncology. A. Ayhan, M. Gultekin, P. Dursun еds. Ankara, 2012. Сh. 29; p. 191–4.2. Shattuck-Eidens D., McClure M., Simard J. et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995;273(7):535–41.Shattuck-Eidens D., McClure M., Simard J. et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995;273(7):535–41.3. Shattuck-Eidens D., Oliphant A., McClure M. et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278(15):242– 1250.Shattuck-Eidens D., Oliphant A., McClure M. et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278(15):242– 1250.4. Miki Y., Swensen J., Shattuck-Eidens D. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.Miki Y., Swensen J., Shattuck-Eidens D. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.5. Wooster R., Bignell G., Lancaster J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–92.Wooster R., Bignell G., Lancaster J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–92.6. Easton D.F., Bishop D.T., Ford D. et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52(4):678–701.Easton D.F., Bishop D.T., Ford D. et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52(4):678–701.7. Neuhausen S., Gilewski T., Norton L. et al. Recurrent BRCA2 617delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13(1):126–8.Neuhausen S., Gilewski T., Norton L. et al. Recurrent BRCA2 617delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13(1):126–8.8. Offit K., Gilewski T., McGuire P. et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643–5.Offit K., Gilewski T., McGuire P. et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643–5.9. Tonin P., Weber B., Offit K. et al. A high frequency of BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nat Med 1996;2(11):1179–83.Tonin P., Weber B., Offit K. et al. A high frequency of BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nat Med 1996;2(11):1179–83.10. Langston A.A., Malone K.E., Thompson J.D. et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334(3):137–42.Langston A.A., Malone K.E., Thompson J.D. et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334(3):137–42.11. Frank T.S., Manley S.A., Olopade O.I. et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16(7):2417–25.Frank T.S., Manley S.A., Olopade O.I. et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16(7):2417–25.12. Stratton M.R., Ford D., Neuhasen S. et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994;7(1):103–7.Stratton M.R., Ford D., Neuhasen S. et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994;7(1):103–7.13. Diez O., Osorio A., Duran M. et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 2003; 22(4):301–12.Diez O., Osorio A., Duran M. et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 2003; 22(4):301–12.14. Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA-1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57(6):1457–62.Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA-1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57(6):1457–62.15. Ford D., Easton D.F., Stratton M.R. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62(3):676–89.Ford D., Easton D.F., Stratton M.R. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62(3):676–89.16. Scott C.L., Jenkins M.A., Southey M.C. et al. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 2003;112(5–6):542–51.Scott C.L., Jenkins M.A., Southey M.C. et al. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 2003;112(5–6):542–51.17. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–6.King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–6.18. Eeles R., Kaduri L. BRCA 1/2 carriers and endocrine risk modifiers. Endocr Relat Cancer 1999;6(4):521–8.Eeles R., Kaduri L. BRCA 1/2 carriers and endocrine risk modifiers. Endocr Relat Cancer 1999;6(4):521–8.19. Ford D., Easton D.F., Bishop D.T. et al. Risks of cancer in BRCA1-mutation carriers Breast Cancer Linkage Consortium. Lancet 1994;343:692–5.Ford D., Easton D.F., Bishop D.T. et al. Risks of cancer in BRCA1-mutation carriers Breast Cancer Linkage Consortium. Lancet 1994;343:692–5.20. Phelan C.M., Lancaster J.M., Tonin P. et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 1996;13(1):120–2.Phelan C.M., Lancaster J.M., Tonin P. et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 1996;13(1):120–2.21. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91(15):1310–6.The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91(15):1310–6.22. Eerola H., Heinonen M., Heikkilä P. et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008; 10(1):17.Eerola H., Heinonen M., Heikkilä P. et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008; 10(1):17.